Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Q1 2018 Market Update

18 Apr 2018 07:00

RNS Number : 2307L
Iofina PLC
18 April 2018
 

 

18 April 2018

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Q1 2018 Market Update

Production at Iofina's New IOsorb® Plant Ramps Up

 

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, today provides an update to the market regarding its activities in the first quarter ("Q1" or the "Period") of 2018, during which the new IO#7 plant began production of iodine.

 

In the Period Iofina produced 118.2 metric tonnes ("MT") of crystalline iodine from its operating Oklahoma based IOsorb® plants, which was in line with Q1 last year (2017: 118.7MT), when five plants were operating. Operations in January and February were impacted by extreme winter weather in Oklahoma and a greater diversion of brine flow, including at IO#5, than had been anticipated. Despite these headwinds, the Company achieved a similar Q1 output compared with the previous year despite not operating IOsorb® plants IO#3 and IO#5, demonstrating improved production efficiencies. Iodine production run-rate for the Group in March was significantly higher than in the first two months of the year.

 

During the Period, Iofina opened its important new IOsorb® plant, IO#7, which began to scale up operations in mid-February and is already contributing significant additional production at more than double the production rate of its predecessor, IO#3. The ramp-up at IO#7 has occurred broadly as expected as Iofina and its brine supply partner continue to work together to maximize brine input and iodine output. As IO#7 optimises its production, the Company expects overall total iodine production rates in Q2 2018 to also increase.

 

Whilst IO#3 has been successfully repurposed to IO#7, a similar determination on the future use of IO#5 is being reviewed. The Company is working with various brine suppliers towards the best utilisation of IO#5, which will either remain at its current location or be relocated to a different site in order to maximise production output while reducing production cost to be a lower quartile producer.

 

Demand for and sales of iodine and iodine based derivatives through Iofina Chemical were as anticipated for the Period. Additionally, Iofina Chemical has added additional chemical reactor capacity for iodide products to meet demands. Prices of iodine and iodine based compounds have risen slightly in the Period continuing their upward trend from 2017.

 

Commenting, President and CEO Dr. Tom Becker, stated: 

''Despite the effects of the weather and brine supply, 2018 iodine production is off to a solid start with the opening of IO#7 midway through the quarter, which is expected to increase output and reduce iodine production costs in Q2 2018. Importantly, commencement of production at IO#7 started on time and management expects output from the plant to increase during the year as it moves to full optimisation. Management continues to review the strategy for IO#5 in order to optimise production from this plant.

 

"The trend of iodine prices continues to move upward and is an additional benefit for Iofina as it moves forward and executes its growth strategy to increase iodine output whilst lowering production costs".

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Emily Morris

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBVVRWWASAAR
Date   Source Headline
5th Jun 20267:00 amRNSAgreement Signed for Additional Brine Water Supply
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.